Plain-English translation of NCT05986240 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called , either by itself or combined with an existing approved medication (Venetoclax), in patients with blood cancers that have stopped responding to their initial treatment. works by blocking a protein in cancer cells that helps them resist treatment and survive. The study will help doctors understand the right dose of this medication and how well it works for people in your situation.
People with relapsed or refractory blood cancers have very limited treatment options and poor survival rates. This medication is designed to work differently than standard treatments, potentially helping patients whose cancers have become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as infusions (intravenous injections) on a schedule that increases over the first week of each 4-week cycle, then continues weekly for the rest of that cycle. You'll have regular blood tests and bone marrow biopsies to monitor how you're responding and to check for side effects. Participation will continue as long as the treatment is helping you and you're tolerating it well.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States